The Duchenne muscular dystrophy (DMD) community is facing increased anxiety as Sarepta Therapeutics reports the second patient death linked to its gene therapy drug, ELEVIDYS. The company, alongside Roche, has paused the clinical and commercial use of the treatment and suspended shipments for non-ambulatory patients. This tragic news has led to significant stock declines for Sarepta, with shares plummeting over 47% following the announcement. In light of the deaths, both companies are implementing steps to enhance safety measures and reassess the ongoing trials of the therapy, which has already raised concerns about fatal liver failures associated with its use.